report molecular and clinical characterizations of six subjects with the reciprocal phenomenon of deletions spanning both genes, i.e., PMP22-RAI1 deletions. Molecular studies utilizing high-resolution array comparative genomic hybridization and breakpoint junction sequencing identified mutational signatures that were suggestive of replicationbased mechanisms. Systematic clinical studies revealed features consistent with SMS, including features of intellectual disability, speech and gross motor delays, behavioral problems and ocular abnormalities. Five out of six subjects presented clinical signs and/or objective electrophysiologic studies of peripheral neuropathy. Clinical profiling may improve the clinical management of this unique group of subjects, as the peripheral neuropathy can be more severe or of earlier onset as compared to SMS patients having the common recurrent deletion. Moreover, the current study, in combination with the previous report of PMP22-RAI1 duplications, contributes to the understanding of rare complex phenotypes involving multiple dosage-sensitive genes from a genetic mechanistic standpoint.
Introduction
DNA rearrangements have been demonstrated to cause gene interruption or fusion by disrupting gene structure, altering the copy number of dosage-sensitive gene(s), or imposing a position effect on the regulation of gene expression; the latter is potentially mediated through altering topologically associating domains (TAD) or effecting long noncoding RNA (lncRNA) (Lupianez et al. 2015; Szafranski et al. 2016 ). Deletion of a genomic segment may unmask recessive mutation(s) on the other allele (Liburd et al. 2001; Wu et al. 2015) . Collectively, diseases mediated by such DNA rearrangements are termed genomic disorders (Lupski 1998 (Lupski , 2009 (Lupski , 2015 Lupski and Stankiewicz 2005) .
Copy number variants (CNVs), including duplications or deletions of a genomic segment on the proximal short arm of human chromosome 17, have been associated with various genomic disorders. Interstitial deletion CNVs on 17p11.2 encompassing RAI1 (MIM: 607642) result in Smith-Magenis syndrome (SMS, MIM: 182290); and a recurrent deletion of ~3.7 Mb in size is observed in 70-80 % of all deletion cases. SMS is a disorder characterized by distinctive physical features including a recognizable pattern of craniofacial dysmorphology, obesity, developmental delay, cognitive impairment, and neurobehavioral abnormalities. Infants often have feeding difficulties, failure to thrive, hypotonia and hyporeflexia. Variable manifestations include congenital heart defects, hearing loss, renal anomalies, scoliosis, short stature, and progressive myopia. The behavioral characteristics include significant sleep disturbance, stereotypies, and self-injurious behaviors, which usually appear after 18 months and continue through adulthood (Neira-Fresneda and Potocki 2015) . Although haploinsufficiency of RAI1 caused by loss of function mutations has been reported as the primary cause for most of the SMS features (Bi et al. 2004 (Bi et al. , 2006 Girirajan et al. 2006; Slager et al. 2003) , phenotype-genotype correlation studies in humans and chromosome-engineered mouse CNV models have proposed that other genes in or beyond the 17p11.2 deletion region may undergo dosage imbalance or perturbed regulation due to the deletion and as a result contribute to the variable expressivity of the syndrome (Bi et al. 2002; Girirajan et al. 2006; Lacaria et al. 2012; Ricard et al. 2010; Yan et al. 2007) .
In a nearby genomic region, a recurrent interstitial deletion of ~1.4 Mb in size on chromosome band 17p12 encompassing PMP22 (MIM: 601097) is associated with hereditary neuropathy with liability to pressure palsies (HNPP, MIM: 162500) (Chance et al. 1993) . Truncating mutations in PMP22 have also been found in subjects with HNPP phenotypes indistinguishable from those with the 1.4 Mb common HNPP deletion (Li et al. 2007) . HNPP is characterized by recurrent entrapment neuropathies such as peroneal palsy with foot drop and carpal tunnel syndrome (Potocki et al. 1999) . The disorder usually presents during the second or third decade, even though it could present atypically in early childhood (Chrestian et al. 2015) . The electrophysiological pattern of HNPP can potentially be quite characteristic with uniform demyelinating sensorymotor polyneuropathy and typical multifocal conduction slowing at sites of entrapment; i.e., conduction block (CB) (Gabreels-Festen et al. 1992) . PMP22 haploinsufficiency may hasten the induction of CB and thus protein product encoded by PMP22 appears to protect the nerve from mechanical injury (Bai et al. 2010) .
The SMS deletion affects the central nervous system (CNS), leading to intellectual disability and behavior abnormalities accompanied by developmental delay and distinctive facial features. The deletion may also have peripheral nervous system (PNS) involvement and manifest signs suggestive of peripheral neuropathies, but with normal nerve conduction velocities (NCVs) in most SMS cases (Greenberg et al. 1991) . HNPP is a mild form of peripheral neuropathy, which may be underdiagnosed due to episodic and transient clinical manifestations (Potocki et al. 1999) . HNPP disease expression, including electrophysiologic manifestations, can be influenced significantly by environmental exposures-as noted in the initial clinical description by "a liability to pressure palsies", mechanical stress to peripheral nerves can elicit a pressure palsy (De Jong 1947; Staal et al. 1965) . However, when both PMP22 and RAI1 are deleted it is plausible to hypothesize that the interplay between CNS and PNS abnormalities may lead to a variable, potentially more severe phenotype blending both SMS and HNPP.
The recurrent SMS and HNPP deletions are generated by nonallelic homologous recombination (NAHR) using flanking low copy repeats (LCRs) as substrates, termed SMS-REPs and CMT1A-REPs, respectively (Chen et al. 1997; Pentao et al. 1992) . These long and highly homologous sequences promote unequal crossover and subsequently result in copy number changes (Dittwald et al. 2013; Liu et al. 2011; Yuan et al. 2015b ). However, since the SMS and HNPP recurrent deletions are delimited by distinct LCR pairs, extensive homologies flanking both SMS and HNPP critical regions as a contiguous segment are lacking.
Interestingly, there have been reports of rare large deletions that encompass both HNPP and SMS loci and include both PMP22 and RAI1 (Goh et al. 2014; Juyal et al. 1996; Liu et al. 2011; Stankiewicz et al. 2003; Trask et al. 1996; Zori et al. 1993) . These deletions have breakpoints that are potentially beyond the regions defined by the LCR-mediated NAHR; thus, a different mutational mechanism may be considered and investigated. Moreover, because different spectrums of gene contents are involved in these large deletions, we provided a comprehensive documentation of the clinical profiles of the subjects with PMP22-RAI1 contiguous gene deletions. The study of PMP22-RAI1 deletions (N = 6 reported herein) complements our previous report of PMP22-RAI1 duplications (N = 23, Yuan et al. 2015a) , both from the molecular and clinical perspectives.
Subjects and methods

Human subjects
A total number of 132 subjects with chromosome 17p11.2 deletion were enrolled in a research protocol approved by the Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals. Informed consent was obtained from the subjects and parents or legal guardians of the subjects. All genomic studies, including array CGH and breakpoint junction sequencing, were performed on DNA samples extracted from whole blood.
Six of 132 subjects were identified with larger deletions encompassing both PMP22 and RAI1, deletions of which are responsible for HNPP and SMS, respectively. BABs 484, 608, 993, and 2011 were published with molecular mapping and/or clinical findings Liu et al. 2011; Stankiewicz et al. 2003; Zori et al. 1993) ; among these, breakpoint junction sequence was previously obtained for BAB2011 . BABs 8499 (also known as SMS530) and 8501 were not reported previously. Detailed clinical records were available from 6/6 subjects for review. Detailed clinical information is listed in Supplemental Table 1 .
Array comparative genomic hybridization (aCGH) and breakpoint junction sequencing aCGH with high-density coverage of the proximal 17p region was designed to interrogate CNVs with high resolution. Array design (AMADID# 032121), experimental procedures, aCGH data analysis, and breakpoint junction sequencing methods were performed as described (Yuan et al. 2015a ). Breakpoint junction sequences were mapped to hg19.
Mosaicism quantification by aCGH
The mosaicism level of deletion on autosomes (α) was calculated based on aCGH log 2 ratio (LR), which was the mean LR of all probes involved in the genomic segments that were deleted:
Results
We characterized deletion CNVs overlapping chromosome 17p11.2 in 132 cases with a molecular and clinical diagnosis of SMS. NAHR-mediated common recurrent SMS deletion (CR) was identified in 96 (72.7 %) cases; uncommon recurrent deletions 1, 2 and 3 (UR1, UR2 and UR3) were identified in eight (6.1 %), two (1.5 %) and two (1.5 %) cases, respectively (Fig. 1) . We identified nonrecurrent
deletions (NR) with unique CNV boundaries nonetheless spanning RAI1 in 24 (18.2 %) subjects. Among these NR deletions, we identified six (6/24, 25.0 %) subjects with deletions encompassing both PMP22 and RAI1, termed PMP22-RAI1 contiguous gene deletion, or in short PMP22-RAI1 deletion (Fig. 1b, in red) . These deletions range from 4.6 to 9.4 Mb, with the smallest region of overlap (SRO) of ~2.8 Mb spanning PMP22 and RAI1 in one genomic segment (Fig. 2a) . No other submicroscopic CNVs were observed in these six cases based on genome-wide chromosome microarray analysis (CMA data not shown). Breakpoint junction sequencing was attempted for the PMP22-RAI1 deletions in these six subjects in order to map the CNV boundaries to nucleotide-resolution and surmise potential molecular mechanisms. Microhomologies of different lengths were identified at the breakpoint junctions of BAB2011 (1 bp, C) and BAB8499 (6 bp, ACCACC) ( Fig. 2b ; Table 1 ), consistent with fork stalling and template switching/microhomology-mediated break-induced replication (FoSTeS/MMBIR) (Hastings et al. 2009; Lee et al. 2007; Zhang et al. 2009 ). Microhomology-mediated end-joining (MMEJ) may be an alternative explanation, as microhomologies were identified at the breakpoint junction (McVey and Lee 2008).
We were not able to experimentally determine the precise breakpoint junctions for BABs 484, 608, 993 and 8501, because the deletions in these cases had one boundary located in regions clustered with LCRs (17p-PROX for BABs 484, 608 and 993, RNU3 LCRs for BAB8501, Fig. 1 ), limiting the ability to uniquely define the locus of the breakpoint junction. It has been proposed that complex genomic architectures may catalyze nonrecurrent genomic rearrangement and cluster their breakpoints in the vicinity of LCRs (Carvalho and Lupski 2016; Stankiewicz and Lupski 2010) . The 17p proximal region is enriched with LCRs, which constitute higher-order complex features of this region and thereby promote genomic instability and mediate recurrent (NAHR) and stimulate nonrecurrent (via template switching) rearrangement events that lead to CNVs (Stankiewicz et al. 2003; Yuan et al. 2015a) .
Using high-resolution aCGH data, we were able to reanalyze the CNV boundaries and estimate if they were embedded in regions of LCRs. In the cohort of 132 subjects identified with 17p11.2 deletions, LCR-mediated NAHR are responsible for the recurrent deletions including 96 CR, eight UR1, two UR2 and two UR3. For the remaining 24 NR deletions, at least 14/24 (BABs 608, 484, 8501, 993, 572, 1140 (BABs 608, 484, 8501, 993, 572, , 641, 1221 (BABs 608, 484, 8501, 993, 572, , 1195 (BABs 608, 484, 8501, 993, 572, , 255, 1931 (BABs 608, 484, 8501, 993, 572, , 1774 (BABs 608, 484, 8501, 993, 572, , 566, 1615 had one boundary localized within regions of LCRs (Fig. 1 ). Among these, 6/14 (BABs 1140 (BABs , 255, 1931 (BABs , 1774 (BABs , 566 and 1615 had one boundary inside the proximal SMS-REP; while 3/14 (BABs 608, 484 and 993) had one boundary inside the 17p-PROX region, which is composed of 1 3
LCRs sequences flanking an ~141 kb stretch of microsatellite DNA sequences possibly responsible for the nonrecurrent rearrangements identified in the 17p proximal region (Yuan et al. 2015a ).
We performed phenotype-genotype correlation studies to specifically describe the clinical profiles of the six subjects harboring the PMP22-RAI1 deletion. Clinical features are summarized as Table 2 . In general, among these subjects, the age of the latest evaluation was variable, ranging from 2 years to mid-20s. The most common features shared among these subjects were intellectual disability, speech and gross motor delays, behavioral problems and ocular abnormalities, which were consistent with features of SMS.
We further studied the severity of peripheral neuropathy as well as a potential spectrum of phenotypes broader than those usually observed in either SMS or HNPP in these subjects. We also compared the clinical features of these subjects with the reported SMS features from published phenotype-genotype correlation studies (Edelman et al. 2007; Girirajan et al. 2006; Greenberg et al. 1991 Greenberg et al. , 1996 (Supplemental Tables 1 and 2 ). Two of six subjects (BABs 484 and 608) had a diagnosis of peripheral neuropathy. BAB484, who harbors an 8.0 Mb deletion, had decreased deep tendon reflexes (DTRs) along with a moderate motor slowing (MCV 23.9 m/s) of both proximal median nerves with no sensory abnormalities on nerve conduction studies The incidence counts of each genomic rearrangement are shown on the right panel. (NCS) at the age of 28 months. At 47 months her nerve conductions studies were reportedly within normal limits. Later in life at about 6 years of age she was given a clinical diagnosis of HNPP based on her symptoms, as well as prediction from her cytogenetic results. BAB608, whose deletion of 9.4 Mb was the largest among the subjects of this study, presented on clinical evaluation with motor delay, delayed walking and normal DTRs. This same subject had nerve conduction studies that showed a generalized peripheral nerve involvement including abnormalities of motor and sensory conduction of both lower extremities, suggesting Charcot-Marie-Tooth disease (CMT) but was later diagnosed with HNPP. One additional subject (BAB993), who has a 6.9 Mb deletion, presented on exam with pes planus, normal deep tendon reflexes, and abnormal gait, along with slowing in motor conduction velocities in both median nerves. The remaining subjects analyzed did not have NCS performed, but among these remaining individuals two additional subjects (BABs 2011 and 8499) were reported with abnormal gait, frequent falling, foot deformities and decreased sensitivity to pain, requirement of shoe inserts and orthotic interventions. Age of walking for these six subjects ranged from 18 to 36 months. One subject (BAB8501) did not present any readily apparent clinical signs of peripheral neuropathy at the most recent examination at age of 23 years. Few other congenital anomalies were reported among these subjects. Ophthalmologic abnormalities were by far the most common including myopia, strabismus, iris abnormalities and retinal detachment. Congenital heart malformation was reported in two out of six subjects (BABs 484 and 608). No renal abnormalities were identified within the chart review. BAB484 was found to have moderate hydrocephalus on brain MRI, involving the lateral, third and fourth ventricles. BAB993 had prominence of the ventricular system, as previously reported in 9/25 patients with SMS .
In our study, we also used aCGH to investigate the DNA isolated from the blood sample of BAB485, the mother of BAB484, who was reported in the past to have a mosaic PMP22-RAI1 deletion characterized by karyotyping (Zori et al. 1993 ). The mosaicism level was quantified to be 57 % by aCGH, which was consistent with the quantification by karyotyping (Zori et al. 1993) . The clinical features of BAB485 are not consistent with SMS, but she did have some facial dysmorphism as well as pes cavus but normal DTRs. Her nerve conduction studies did not show any evidence of peripheral neuropathy. In contrast to BAB485, one mosaic case for the PMP22-RAI1 deletion reported by Goh et al. (Goh et al. 2014 ) did have facial features and developmental delays consistent with SMS, as well as hyporeflexia. NCS studies at the age of 7.5 years confirmed polyneuropathy. However, NCS values were not provided in the report.
Discussion
Genomic architecture with features of LCRs/segmental duplications and repetitive sequences (such as Alus) may predispose to rearrangements. In addition to providing extensive homology for NAHR, LCRs may contribute to genomic instability and template switches leading to nonrecurrent rearrangements with breakpoints grouping at LCR regions via mechanisms other than NAHR (Carvalho and Lupski 2016 (Shaw and Lupski 2005) . The evidence suggests that replication-based mechanism or non-homologous end joining, rather than homologous recombination, generate these deletions. Satellite DNA sequences, one type of repetitive sequences, may mediate rearrangements by inducing DNA breakage followed by erroneous DNA repair (Page et al. 1996) . Moreover, Alu repetitive elements have been shown to facilitate template switching during Alu-Alu mediated, disease-associated rearrangements and in a yeast replicative repair assay (Boone et al. 2011 (Boone et al. , 2014 Mayle et al. 2015; Shaw and Lupski 2005) . Sequencing of the breakpoints in LCR and repetitive sequences may provide further evidence consolidating the hypothesis that LCRs facilitate replicative repair-mediated rearrangements (Eid et al. 2009; English et al. 2015; Wang et al. 2015) . Unlike NAHR-mediated recurrent CNVs with boundaries confined by flanking LCRs, nonrecurrent CNVs may have variable boundaries and thus include variable gene content. An "atypical" CNV of a known genomic disorder may span additional genomic segments, change the copy number of neighboring dosage-sensitive disease-associated gene(s), and subsequently result in a complex phenotype blending multiple disorders (Table 3) . For example, large, nonrecurrent duplications encompassing both PMP22 and RAI1 (PMP22-RAI1 duplication) have been described in Yuan-Harel-Lupski syndrome (YUHAL, MIM: 616652) presenting a combination of Potocki-Lupski syndrome (PTLS, MIM# 610883) and Charcot-Marie-Tooth disease type 1A (CMT1A, MIM: 118220) traits with a potential more severe and early-onset peripheral neuropathy (Yuan et al. 2015a) .
Here, we documented the reciprocal phenomenon: i.e., PMP22-RAI1 deletions. A larger deletion may give rise to a complex phenotype by affecting multiple disease-associated loci via a combination of possibilities, including (1) spanning multiple loci associated with dominant disorders (Campbell et al. 2012) , (2) unmasking recessive loci (Liburd et al. 2001) , and (3) causing gene fusion (Segal et al. 1999) . For example, large deletions spanning the tuberous sclerosis complex (TSC, MIM: 613254) gene TSC2 (MIM: 191092) and autosomal dominant polycystic kidney disease (ADPKD, MIM: 173900) gene PKD1 (MIM: 601313), two genes mapped "head-to-head" on chromosome 16p, result in early-onset polycystic kidney disease with tuberous sclerosis (MIM: 600273), a mixed phenotype with both TSC and ADPKD traits (Brook-Carter et al. 1994) . Similarly, large deletions resulting in more severe and complex phenotypes have been reported at other loci typically associated with recurrent deletions, such as the BMPR1A locus and the STS locus (Ballabio et al. 1989; van Bon et al. 2011) . In rare circumstances of diffuse leiomyomatosis with Alport syndrome (MIM: 308940), a deletion includes part of COL4A5 and results in Alport syndrome by a gene dosage-effect. In addition, this deletion also spans part of the neighboring gene COL4A6, creates a fusion gene between COL4A5 and COL4A6 and thereby leads to diffuse leiomyomatosis (Table 3) .
It is expected that subjects with a large deletion encompassing RAI1 and PMP22 will manifest a resultant phenotype that consists of combined features of SMS and HNPP. Among our six subjects, two of them had a clear diagnosis of peripheral neuropathy at the time of latest examination. Some of these subjects were last examined during their first decade of life and thus may not have yet developed signs and symptoms of peripheral neuropathy. HNPP is an adultonset neuropathy that usually presents during the second or third decade. Early signs could have potentially been perceived on NCS; however, this test was not performed on every subject.
The severity of phenotype may correlate with the size of the deletion as well as the level of mosaicism. We observed Table S1  Table 2 COL4A6 Point mutation XLR a more severe neuropathy phenotype among the subjects with larger deletions (BABs 484, 608 and 993, and the subject reported by Goh et al.) , among which BAB993 had the smallest deletion of 6.9 Mb in size. These subjects were given a clinical diagnosis of HNPP, or otherwise had symptoms such as delayed walking, hyporreflexia, foot deformities and/or abnormal velocities on NCS. Even though there was a large age gap between some of these subjects, they showed signs of peripheral neuropathy during their first decade of life. Interestingly, subjects whose deletions were smaller than 6.9 Mb did not have NCS performed, possibly because these were not clinically indicated. Thus, even if their symptoms and clinical presentation of neuropathy seemed much milder or even absent, we could not rule out motor and sensory abnormalities that could potentially be identified by NCS. Mosaic deletions spanning both SMS and HNPP critical regions have been reported. These mosaic deletions were all uniquely observed, likely arose from postzygotic and mitotic rearrangements, and contributed to variable phenotypes. Quantified by fluorescence in situ hybridization, Goh et al. reported a mosaic ~7.4 Mb PMP22-RAI1 deletion with mosaicism level of 12 % in a 15-year-9-month-old female subject with polyneuropathy and clinical diagnosis consistent with SMS (Fig. 3a) . In our study, the mother of BAB484 (BAB485) harbored a mosaic PMP22-RAI1 deletion with mosaicism level of 57 % quantified by aCGH (Fig. 3b) (Zori et al. 1993 ). However, she had very mild phenotypes that were not consistent with SMS. It is interesting that the level of mosaicism as measured in genomic DNA of cells isolated from blood did not seem to correlate with the severity of the phenotype in the two mosaic cases being compared. One possible explanation is that the organ distributions of mosaicism were different in these two individuals, with possible higher level in the neurological system of the subject reported by Goh et al. It needs to be considered that the patient reported by Goh et al. also harbored a mosaic duplication on 17q. Although this duplication was not yet associated with a defined phenotype, it may aggravate the phenotype of this patient. These two observations, albeit limited data on only two subjects, might suggest that mosaic PMP22-RAI1 deletion may have distinct phenotypic outcomes, ranging from nonsymptomatic to a phenotype with features combining both HNPP and SMS. Although mosaicism may not lead to clinical presentation of SMS and HNPP, it affects the recurrence risk of the disorder in offspring. In a previous study, an unaffected mother with a mosaic deletion allele encompassing the last two exons of RAI1 found in 25.1 % of maternal blood cells, gave birth to three affected half siblings with SMS, including a male patient from one father and fraternal male and female twins from another father, with the same exonic deletion . Therefore, molecular testing is recommended for the apparently unaffected parents with a child harboring nonrecurrent deletions to inform potential recurrence risk. PMP22-RAI1 duplications outnumbered deletions. The PMP22-RAI1 duplication was observed in 23/127 subjects with PTLS, in comparison to PMP22-RAI1 deletion observed in 6/132 subjects with SMS (Fisher's exact test, p < 0.001). Brewer et al. compared autosomal copy number duplication versus deletion generated from low-resolution chromosome analysis. Their studies revealed that the potential triplolethal regions (2.1 % of the haploid autosomal length [HAL] ) were less than the potential haplolethal regions (11 % of HAL). Moreover, the longest duplication represented 4.3 % of HAL in comparison to 2.7 % of HAL for the longest deletion. Furthermore, the longer duplications/deletions are less frequently observed in the analyzed population (Brewer et al. 1998 (Brewer et al. , 1999 . These findings suggest that deletions are potentially less tolerated than duplications. Larger deletions, such as the PMP22-RAI1 deletion, may be more lethal, because they have a higher chance to include more haploinsufficient genes or unmask recessive mutations on the other allele. The observance of one mosaic patient by Goh et al. (2014) also indicates possible cell lethality of the PMP22-RAI1 deletion, which may include potential not-yet-identified essential genes mapping to this locus.
In summary, we documented six patients with nonrecurrent deletion encompassing both HNPP and SMS loci. Our genomic analyses suggest replicative mechanisms as a predominant mechanism underlying PMP22-RAI1 contiguous gene deletion syndromes, i.e., both gains and losses, and provide further evidence supporting the role of complex genomic architecture in genomic instability. Detailed clinical profiling may contribute to the clinical management of this unique group of subjects. Furthermore, our study may contribute to the understanding of complex phenotypes involving multiple disease-associated loci from a mechanistic standpoint.
